AAA’s expertise in developing, producing and commercializing nuclear medicine theragnostics stems from our more than 15-year legacy as a leader in radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).
AAA currently markets 1 therapeutic product (in Europe and the U.S.) and 9 diagnostic products (8 in Europe and 1 in the U.S.), mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.
Our business is structured to improve efficiencies and drive innovation. We are able to generate or reliably source radioisotopes such as fluorine 18 (F 18) and lutetium 177 (Lu 177) using our own facilities. We also conduct much of our own research and development, in addition to having in-house commercial manufacturing and marketing capabilities.
AAA currently has 19 production facilities in 8 countries that manufacture both diagnostic and therapeutic molecular nuclear medicine products. We have:
- 14 PET production sites
- 4 therapeutic production sites
- 2 SPECT production sites
- 1 enriched water production site
- 1 independent lutetium 177 manufacturing business
All of our manufacturing facilities conform to current good manufacturing practices or cGMP. This network provides the basis for our advanced manufacturing capacity, cost-efficient production, and organization of reliable product distribution.